SAN FRANCISCO—CollabRx Inc. and Cynvenio Biosystems Inc. have begun a multiyear agreement to utilize CollabRx technology and content resources to support the clinical interpretation of genetic sequencing-based tests by Cynvenio. Per the terms of the agreement, several CollabRx products, including the Genetic Variant Annotation (GVA) Service, will be paired with tumor mutation profiling performed by Cynvenio. Reports generated with the GVA Service will be offered with Cynvenio’s ClearID Breast Cancer blood test, and Cynvenio will combine the test results with clinically actionable data provided by the GVA Service. Thomas Mika, chairman, president and CEO of CollabRx, noted that, “We chose to extend CollabRx expertise and services to ‘liquid biopsy’ for the first time with Cynvenio because they are at the forefront of the sector with a strong focus on advancing personalized medicine in cancer.”